Digital Wearable Walking Aid for Freezing of Gait in Parkinson´s Disease
- Conditions
- Parkinson Disease
- Interventions
- Behavioral: Intelligent cueingBehavioral: Feedback about the number of steps
- Registration Number
- NCT03978507
- Lead Sponsor
- Tel-Aviv Sourasky Medical Center
- Brief Summary
The objective of this study is to investigate the effects of relatively long-term use of a wearable device that provides personalized and intelligent cues (e.g. only when FOG is detected) on FOG.
- Detailed Description
The objective of this study is to investigate the effects of relatively long-term use of a wearable device that provides personalized and intelligent cues (e.g. only when FOG is detected) on FOG. It is hypothesized that the use of this device will reduce FOG in the home and in the community more than in a group of freezers who only receive basic gait information unrelated to FOG-episodes.
This study is a single- blinded bi-centric randomized controlled trial, consisting of 4 weeks of intervention, pre- and post- assessments and free-living monitoring. For this purpose, the DeFOG system was developed through a collaboration between our research group, the Sourasky Medical Center Tel Aviv and mHealth Technologies Bologna, Italy. The system consists of a smartphone, 2 foot-mounted inertial measurement units (IMU's) and earphones which enable transmitting feedback and auditory cues for gait, when FOG is about to occur. The patients will be randomized into an intervention group (DeFOG group) or a control group (N=31 per group). All patients will wear the DeFOG system (mHealth Technologies, mHT) and both groups will receive feedback about the daily number of steps produced. But, only the DeFOG group will receive cueing following detection of FOG. The cueing consists of a metronome, and if FOG persists, also a verbal instruction will be delivered. A therapist will personalize the settings of the DeFOG system and will support the patients in using the system (for instance in coping with false positives). Pre- and post- assessments will be performed by a blinded researcher, both before and after taking medication (in OFF and ON medication state, respectively), consisting of FOG-provoking tasks and questionnaires. During the post-assessment, the FOG provoking protocol will be repeated in both groups with and without the cueing option of the DeFOG system in the home situation.
If therapists involved in the trial note an increase of falls throughout the trial, then it can be decided to involve an interim analysis of the data monitoring committee.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 62
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description DeFOG group Intelligent cueing feedback number of steps + cueing Control group Feedback about the number of steps feedback number of steps DeFOG group Feedback about the number of steps feedback number of steps + cueing
- Primary Outcome Measures
Name Time Method Changes in severity of the freezing of gait phenomenon: percentage time frozen (%TF) immediate post-intervention %TF is determined based on video annotations of the full FOG-provoking protocol (OFF+ON) during the pre- and post-intervention assessment (T1 and T2). %TF = (summed duration FOG during FOG-provoking protocol ON+OFF)/(total duration FOG-provoking protocol OFF+ON)\*100%. Freezing includes episodes of akinetic FOG, trembling FOG and festination.
- Secondary Outcome Measures
Name Time Method Change in number and duration of FOG episodes (video-based) immediate post-intervention The number and duration of FOG episodes as determined based on annotations of video recordings of the FOG-provoking protocol, both OFF and ON medication, during the pre- and post-intervention assessment (T1 and T2).
Changes in physical activity, as recorded using an accelerometer placed on the lower back. One week post-intervention Physical activity will be determined based on recordings using an accelerometer placed on the lower back for 7 days (Axivity; AX3: 3-Axis Logging Accelerometer or AX6: 6-Axis Logging Accelerometer). Outcome measures include the number of steps, the number of bouts of physical activity and the duration of bouts of physical activity. The Axivity sensor is placed before the start of the pre- and post intervention assessment (T1 and T2) and will record continuously for 7 days (during the monitoring weeks).
Change in balance: score on the MiniBESTest immediate post-intervention Change in score on the Mini-Balance Evaluation Systems Test (MiniBESTest), as assessed during the pre- and post-intervention assessment while ON-medication. The MiniBESTest consists of 14 items designed to measure balance performance during mobility tasks related to daily activities. Each item receives a score of 0 to 2, where a score of 0 represents an inability to complete the item and a score of 2 represents the ability to complete the task independently. The range of scores is 0-28, with a higher score representing worse balance impairments.
Changes in Timed Up and Go (TUG) test Performance (sec) immediate post-intervention Change in the duration to perform the Timed-Up and Go (TUG) test in seconds, with and without a cognitive dual task (serial-3 subtraction), both OFF- and ON-medication. The Timed Up and Go performance is a measure of mobility, and a longer duration to perform the task represents a more impaired mobility. The TUG test is administered as part of the FOG-provoking protocol, during the pre- and post-intervention assessments (T1 and T2).
Changes in 4 meter walk test (4MW) performance (sec) immediate post-intervention Change in the duration to walk 4 meters (in seconds), both OFF- and ON-medication. The full 4 meter walk test (4MW) back and forth with turn consists of 5 meters (0.5 meter acceleration, 4 meter steady state walking, 0.5 meter deceleration, a turn on the spot, and then again 0.5 meter acceleration, 4 meter steady state walking and 0.5 meter deceleration). The duration to walk 4 meters before and after the turn will be determined based on video annotations and averaged. The 4MW is administered as part of the FOG-provoking protocol, during the pre- and post-intervention assessments (T1 and T2).
Changes in severity of the freezing of gait phenomenon: %TF OFF medication immediate post-intervention %TF is determined based on video annotations of the OFF-phase of the FOG-provoking protocol during the pre- and post-intervention assessment (T1 and T2). %TF = (summed duration FOG during FOG-provoking protocol OFF)/(total duration FOG-provoking protocol OFF)\*100%. Freezing includes episodes of akinetic FOG, trembling FOG and festination.
Changes in severity of the freezing of gait phenomenon (subjective measurement): score on new Freezing of Gait questionnaire (NFOG-Q). immediate post-intervention The change in the score on the New Freezing of Gait questionnaire (NFOG-Q), which is the revised version of the original Freezing of Gait Questionnaire. The NFOG-Q consists of 9 items, and the maximum score is 28. Higher scores correspond to more severe perceived FOG. The NFOG-Q is administered during the pre- and post-intervention assessments (T1 and T2).
Changes in severity of the freezing of gait phenomenon: %TF ON medication immediate post-intervention %TF is determined based on video annotations of the ON-phase of the FOG-provoking protocol during the pre- and post-intervention assessment (T1 and T2). %TF = (summed duration FOG during FOG-provoking protocol ON)/(total duration FOG-provoking protocol ON)\*100%. Freezing includes episodes of akinetic FOG, trembling FOG and festination.
Change in motor function: score on the MDS-UPDRS part III immediate post-intervention Score on the Motor Examination (part III) of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), assessed both OFF and ON-medication during the pre- and post-intervention assessments (T1 and T2). MDS-UPDRS is a tool to measure the severity and progression of Parkinson disease (PD). Part III is a motor examination consisting of 14 items, each rated on a 5-point Likert type scale (ranging from 0 to 4), with higher scores indicating more severe impairment. The maximum UPDRS part III score is 132, with higher score representing worse motor disability from PD.
Trial Locations
- Locations (2)
Catholic University (KU) Leuven
🇧🇪Leuven, Flamish-Brabant, Belgium
Labrotory for Gait and Neurodynamics, Movement Disorders Unit, TASMC
🇮🇱Tel Aviv, IL, Israel